AzTrials
AzTrials

Gestational Diabetes Mellitus in PregnancyNCT03961542

Effects of Chewing Gum on Glycaemic Control in Women With Gestational Diabetes

A study testing Chewing in people with Gestational Diabetes Mellitus in Pregnancy, run by Medical University of Vienna at 1 site in Austria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
What is being tested?
Chewing
Could I receive a placebo?
No, everyone receives an active treatment
How many people
74 participants
Where
1 siteAustria
Study dates
22 Dec 2017to 10 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • -

Who cannot join

  • Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
  • History of bariatric surgery or surgeries that induce malabsorption
  • HIV- or hepatitis infection
  • Decreased liver or kidney function (before pregnancy)
  • history of malignant disorders
  • Abuse of toxic substances
Show all 10Show fewer
  • Use of systemic steroids
  • Active smoking status during pregnancy
  • Multiple pregnancy
  • Ovulatory drugs and in-vitro fertilisation

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Christian Göbl

    Vienna, 1090

Other trials in Austria

About this study

This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.

Differences in fasting glucose and longitudinal changes over the study period should be additionally examined.

Read the detailed description

Study design and participants This study is designed as an open-label, mono-centre randomized controlled trial with two parallel groups including a total of 74 female patients with recent diagnosis of GDM. Diagnosis of GDM is made in accordance with the IADPSG criteria between 24+0 and 27+6 weeks of gestation [IADPSG 2010]. All pregnant females (aged

between 18 and 45 years) will be recruited consecutively among women visiting our pregnancy outpatient department (Department of Obstetrics and Gynecology, Division of Obstetrics and fetomaternal Medicine, Medical University of Vienna).

Exclusion criteria

  • Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
  • History of bariatric surgery or surgeries that induce malabsorption
  • HIV- or hepatitis infection
  • Decreased liver or kidney function (before pregnancy)
  • history of malignant disorders
  • Abuse of toxic substances
  • Use of systemic steroids
  • Multiple pregnancy

Treatment and Interventions Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement

(fasting as well as 1h after starting each meal). Capillary blood glucose profiles are re- evaluated seven days after starting the blood glucose monitoring.

Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).

Randomisation Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m2); ii. overweight (BMI 26 - 30 kg/m2); iii. obesity (BMI and above 30 kg/m2).

Medical history and baseline examination A broad risk evaluation will be performed in participating females at the initial contact (between 24+0 and 32+0 weeks of gestation) including: evaluation of maternal age, parity, history of GDM, detailed family history, ethnicity, preconceptional diseases, use of ovulation drugs, obstetric history. Moreover, an evaluation of preconceptional weight and BMI as well as measurement of blood pressure will be performed.

Assessment of dietary patterns Dietary patterns will be assessed at baseline (visit 1) by using a published and validated Food-Frequency-Questionnaire (FFQ) proposed by the German Robert Koch Institute [Haftenberg 2010]. It was also previously used for the German DEGS project (www.degs-studie.de). Information from the FFQ will be analyzed quantitatively or summarized by eating scores proposed in the literature (such as the Healthy Eating Index 2010 or Alternate Healthy Eating Index 2010) reflecting diet quality based on actual guidelines [Guenther 2013, Chiuve 2012]. In addition all patients will be advised to conduct a nutritional protocol for seven days. D. End Points

The three primary end points of this study are the averages (arithmetic mean values) of five days 1h postprandial capillary blood glucose measurements: after breakfast (primary end point 1), lunch (primary end point 2) and dinner (primary end point 3).

Secondary end points are fasting glucose concentrations and longitudinal changes (i.e.

assessment of group by time interactions in fasting and postprandial glucose trajectories) as well as changes in dietary patterns.

  1. Statistical Analysis

Sample size With a sample size of n=35 subjects per group we are able to detect a mean difference of 8 mg/dl in postprandial glucose levels with a power of 81% and a type 1 error of α=0.016 for a two-sided unpaired student's t-test, providing a standard deviation of 10 mg/dl in accordance with [Landon 2009]. In order to achieve a 95% coverage probability, the Bonferroni correction will be used to adjust for multiple testing (three primary outcomes). Considering a drop-out rate of 5% n=74 cases are required for this study. A sample size review and adaptation is planned after 50% of the subjects have been investigated.

Analysis Plan Categorical variables will be summarized by counts and percentages; continuous variables data are summarized by means and standard deviations (SD) or by median and interquartile range in the case of strong deviations from the normal distribution.

Statistical comparison of continuous parameters (e.g. postprandial or fasting glucose concentrations) will be performed by the two-sample t-test or nonparametric

approaches (e.g. the Brunner-Munzel test), respectively. An adjustment for demographic variables (such as age) will be performed in case of significant group differences using analysis of covariance (ANCOVA) or by the proportional odds model, if the normality assumption is violated. Linear mixed effects models will be used to assess longitudinal changes of parameters of interest (i.e. fasting and postprandial glucose). Interaction terms are included in the longitudinal models to assess group differences and variable transformations (e.g. logarithmic or square root transformation) are used if necessary. A two-sided p-value ≤0.05 is considered statistically significant. Using the Bonferroni correction for multiple statistical testing (three hypotheses) this results in a 98.33% confidence interval to achieve a 95% simultaneous coverage probability. All analyses will be performed by using the statistic software R and contributing packages [R Core Team 2016].

Being tested
Chewing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ChewingOther

    Also called chewing, gum, blood glucose

    Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).

Study groups in NCT03961542
Study groupRoleWhat they receive
Intervention GroupExperimentalThis study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study. Differences in fasting glucose and longitudinal changes over the study period should be additionally examined.
Receives: Other: Chewing
Control GroupNo interventionParticipants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. blood glucose measurements after with or without chewing

    1hour postprandial capillary blood glucose measurements

    Measured: for one week (7 Days) after breakfast, lunch and dinner

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2019
  2. Study start22 Dec 2017
  3. Primary completion30 Nov 2018
  4. Study completion10 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
74 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03961542
Sponsor's protocol ID
20171218
Status last verified
May 2019
First submitted
20 Jan 2019
Last updated
23 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Yerlikaya-Schatten G, Trimmal L, Rosicky I, Husslein P, Schatten C, Eppel D, Eppel W, Tura A, Gobl CS. Effects of gum chewing on glycaemic control in women with gestational diabetes mellitus: A randomized controlled trial. Impact of chewing on hyperglycaemia in women with GDM. Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:61-65. doi: 10.1016/j.ejogrb.2020.02.003. Epub 2020 Feb 9.

    PubMed 32070847

Questions about this trial

What is this clinical trial studying?

A study testing Chewing in people with Gestational Diabetes Mellitus in Pregnancy, run by Medical University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

blood glucose measurements after with or without chewing (time frame: for one week (7 Days) after breakfast, lunch and dinner). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03961542, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in